<DOC>
	<DOC>NCT03061097</DOC>
	<brief_summary>This study, a Randomized controlled trial of Autologous microbiome reconstitution to prevent Colonization by antibiotic rEsistant bacteria (RACE), seeks to investigate the safety, feasibility and the role of autologous fecal microbiota transplantation (FMT) for the prevention of antibiotic resistant bacteria (ARB) through microbiome restoration.</brief_summary>
	<brief_title>Autologous Fecal Microbiota Transplantation to Prevent Antibiotic Resistant Bacteria Colonization</brief_title>
	<detailed_description />
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibiotics, Antitubercular</mesh_term>
	<criteria>Inclusion criteria for study enrollment 1. Longterm care residents in Boston 2. Adults (18 years or older) Inclusion criteria for randomization 1) Infection requiring antimicrobial treatment at the discretion of the treating physician Exclusion criteria for study enrollment 1. Oral or intravenous antibiotic exposure within previous 6 weeks of stool collection date Topical antibiotic will be permitted 2. Pregnant. Participants of childbearing age will undergo urine pregnancy testing. 3. Participant or substitute decision maker unable to provide informed consent 4. Active gastrointestinal infection at stool collection 5. Fever at the time of stool collection 6. Patients with allergies to following ingredients Generally Recognized as Safe: glycerol and sodium chloride 7. Life expectancy &lt;6 months 8. Unable to adhere to protocol requirements 9. Any condition that the physician investigators deems unsafe, including other conditions or medications that the investigator determines puts the participant at greater risk from FMT 10. Stool culture positive for common enteric pathogens (Salmonella spp., Shigella spp., Campylobacter spp.) 11. Recent travel (last six months) to high risk regions based on the International SOS Medical Risk Rating system 12. Recent exposure (last six months) to unsafe drinking water Exclusion criteria for randomization History of gastrointestinal (GI) symptoms such as (but not limited to) vomiting or diarrhea within 30 days of collection of enrollment stool AND enrollment stool testing positive for one or more of Vibrio spp., Norovirus, Rotavirus, Adenovirus, or Shiga toxin Colonized with CRE (assessed by PCR assay on stool collected at biobanking phase) Colonized with VRE (assessed by PCR assay on stool collected at biobanking phase) Colonized with ESBL (assessed by PCR assay on stool collected at biobanking phase) Colonized with CDI (assessed by EIA assay on stool collected at biobanking phase) Treatment with antibiotics which are active against MRSA (i.e. vancomycin or linezolid) prior to randomization to FMT intervention or placebo. Exclusion criteria for capsule delivery; if contraindicated, enema delivery will be offered Dysphagia or inability to swallow 'safety test' capsule History of severe gastroparesis History of severe intestinal obstruction Any condition that the physician investigators deems unsafe</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Autologous Fecal Microbiota Transplantation</keyword>
</DOC>